Galderma Group (GALD.SW) Stock Price

Galderma Group Price

CLOSED
229.11
​
Market closed

Over the last 4 years Galderma Group grew revenue by 14.0% annually, reaching 4.13 B USD. For Galderma Group, the net margin of 12.7% is up versus -5.2% a few years ago. At today's price the dividend yield works out to roughly 0.04%. The payout ratio is around 5% of earnings. The consensus 12-month price target for Galderma Group is 231.36 USD, about 1.0% above where the stock trades today. Of 19 analysts, 15 rate the stock a buy — an overall Buy consensus.

Galderma Group stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Galderma Group business model & stock analysis

Galderma Group AG, headquartered in Switzerland, operates in the healthcare sector, specializing in dermatological treatments and skincare solutions. The company serves global markets with a focus on innovative products for skin health. Listed on the stock exchange in March 2024, Galderma continues to expand its presence in the international healthcare industry.

Frequently asked questions about Galderma Group

Analysts currently set an average price target of 220.66 USD for the Galderma Group stock (median: 231.36 USD), implying -7.0 % versus the latest price. The consensus is based on 19 analyst ratings.

19 analysts currently rate the Galderma Group stock: 15 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Galderma Group to generate revenue of 6.62 B USD and earnings per share of 5.00 USD.

Converted at the current exchange rate, the Galderma Group share trades at 203.89 EUR (229.11 USD).

The expected revenue of Galderma Group is 6.62 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Galderma Group is 1.18 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Galderma Group is currently 45.83. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Galderma Group stock.

The price-to-sales ratio (P/S) of Galderma Group is currently 8.19. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Galderma Group stock.

The Eulerpool Quality Score for Galderma Group is 5/10.

The ISIN of Galderma Group is CH1335392721. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Galderma Group is GALD.SW. The ticker symbol is used to trade Galderma Group shares on the stock exchange.

Fair ValueTerminal
238.27 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website galderma.com
Currency
USD
Initial public offering
Mar 22, 2024
ISIN
CH1335392721
Cusip
H3301B107
Market capitalization
54.43 B USDLarge Cap
52-Week Range
PEG
4.87
P/E ratio
P/Ee 2026
45.97
P/Ee 2027
33.67
P/Ee 2028
26.01
P/Ee 2029
21.10
P/Ee 2030
17.54
P/Se
8.19
EV/EBIT
78.31
P/B Ratio
8.17
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
5.89 %
Dividend
Dividend yield
0.04 %
Est. Dividend Yield
0.04 %
Payout Ratio
4.62 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
1 year
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
35.00 %
Last updated Nov 5, 2026, 10:29 PM

Galderma Group Peer Group